SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma

Published:2024-05-13 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Xu Xianglai¹²³,Lin Jinglai¹²³,Wang Jiahao¹,Wang Ying⁴,Zhu Yanjun¹,Wang Jiajun¹,Guo Jianming¹

Affiliation:

1. Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China

2. Department of Urology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China

3. Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China

4. Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China

Funder

Natural Science Foundation of Fujian Province

National Natural Science Foundation of China

Medical Project of Xiamen

Fudan University

Shanghai Sailing Program

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2350101

Reference45 articles.

1. Renal cell carcinoma

2. Systemic Therapy for Metastatic Renal-Cell Carcinoma

3. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

4. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

5. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors;Cellular Oncology;2024-09-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3